このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE) (SUNRISE)

2026年11月11日 更新者:Biosensors Europe SA

A Prospective, Randomised, Multicenter, Single-Blind Non-Inferiority Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)

Coronary heart disease causes narrowing of the heart (coronary) arteries (arteries are blood vessels, which supply oxygen-rich blood to the heart muscle). Your heart specialist will have explained to you that they suspect that you have a narrowing in one or more of your heart arteries. This narrowing may be causing you to have chest pains or evidence of reduced blood supply to your heart muscle.

One commonly used treatment for this problem is to stretch the narrowing with a balloon and then insert a small mesh-like device called a stent, which will hold the artery open, improving the blood flow to your heart, and thereby help with your symptoms. An alternative treatment is to open the narrowing with a balloon that is coated with an anti-inflammatory drug (so called drug-coated balloon) as treatment instead of a stent. Drug-coated balloons are used to reduce the risk of re-narrowing of your coronary arteries without leaving an implant (like a stent) behind. A stent (which is a foreign object that does not belong in the body) can cause vessel inflammation and it bears the risk of blockage within the stent (in-stent restenosis or ISR). Drug-coated balloons leave no implant behind but target the narrowing in your vessel wall with the delivery of an anti-inflammatory agent to the vessel wall, allowing the blood vessel to heal.

Biosensors has developed a balloon coated with a drug called Biolimus A9™ which suppresses inflammation in the artery where the narrowing has occurred. We refer to this balloon coated with Biolimus A9™ as BA9-DCB (Biolimus A9™ drug-coated balloon) also known as BioRISE. This device is not commercially available and will be tested in this study for the first time in humans. However, several coronary stents made by Biosensors are already on the market that contain the Biolimus A9™ drug. It has been proven to be safe and effective in preventing re-narrowing of the artery where the stent is placed.

In this study, two types of drug-coated balloons (DCBs) will be used; the BioRISE (test group; group 1) and SELUTION SLR, a balloon that is coated with sirolimus (control group; group 2). The SELUTION SLR balloon is commercially available in Europe.

The study has the following design:

• Patients will be treated according to standard hospital procedures using the study device.

The study has the following design:

  • Patients will be treated according to standard hospital procedures using the study device.
  • There will be two different types of patients included in this study.
  • 400 patients with a narrowing in a heart artery that has never been treated before (referred to as de novo disease), of whom 200 will be treated with the BioRISE balloon and 200 with the SELUTION SLR balloon. The allocation to the two possible treatments is random as it must be in a study like this. Of these 400 patients, 15 in each treatment arm, will have the inside of the artery imaged during the procedure using a well-established technique called Optical Coherence Tomography (OCT) and Quantitative Flow Ratio (QFR)
  • 43 patients with a narrowing inside a stent that was implanted in the past (referred to as in-stent restenosis). In these patients, only the BioRISE balloon will be used.
  • Your doctor will explain to which category applies to you.
  • There will be up to 25 hospitals taking part in the study in the UK, and in up to 5 European countries
  • Patients will be taking part in the study for up to 3 years, and during this time their health status will be assessed by telephone or hospital visit at 1month, 9 month, 12 months, 24 months and 36 months.
  • There will be a check up angiography to assess the primary end point at 9 months for all participants.

調査の概要

詳細な説明

Devices used :

Investigational device: BioRISE Biolimus Drug-Coated Balloon. Comparator: SELUTION SLR sirolimus-coated balloon (de novo randomised cohort only).

Purpose and Background:

Coronary drug-coated balloons provide an anti-restenotic effect without a permanent implant. This study evaluates the BioRISE Biolimus Drug-Coated Balloon against an established sirolimus drug-eluting balloon (SELUTION SLR) in de novo coronary lesions, with a supportive single-arm cohort in in-stent restenosis, to generate clinical evidence supporting CE marking under Regulation (EU) 2017/745 (MDR).

Clinical Development stage:

Pre-Market Phase (Interventional) - Pivotal clinical investigation.

Study population:

Patients with de novo coronary artery lesions (randomised cohort) and with in-stent restenosis (single-arm cohort).

Total 443 subjects: 400 randomised de novo (200 BioRISE : 200 SELUTION SLR) plus 43 ISR (BioRISE only), at up to 25 sites in up to 6 European countries.

Design:

Prospective, randomised (1:1), multicentre, single-blind (with blinded angiographic core laboratory and blinded independent CEC adjudication study with an additional single-arm ISR safety cohort.

Objectives:

Demonstrate non-inferiority of BioRISE versus SELUTION SLR for in-segment LLL at 9 months in de novo coronary lesions.

Primary endpoints:

In-segment Late Lumen Loss (LLL) (or Gain) at 9 months Defined as the difference between post-procedural minimal lumen diameter (MLD) and 9-month follow-up MLD, measured by quantitative coronary angiography (QCA), assessed by a blinded angiographic core laboratory.

Analysis segment: in-segment, defined for this study as the balloon-treated segment plus 5 mm proximal and 5 mm distal, consistent with the comparator's pivotal trials (SELUTION DeNovo). ARC-DCB defines in-segment as the treated segment plus 1 mm, the ARC-DCB rationale for in-segment analysis (a proximal and distal buffer zone mitigating geographic miss= applies equally. The core laboratory additionally reports in-segment LLL with the ARC-DCB 1 mm margins.

Primary Endpoint Justification:

Per ARC-DCB, LLL is expected to be reliable when comparing different types of DCBs (DCB vs DCB).

Clinical secondary endpoints

• Clinical secondary endpoints Device-Oriented Composite Endpoint (DOCE; ARC-DCB) at all timepoints: hierarchical occurrence of cardiovascular death, device-failure-related MI (not clearly attributable to a non-target vessel), device-failure-related ischaemia, and clinically driven target lesion revascularisation (TLR).

Lesion-Oriented Composite Endpoint (LOCE; ARC-DCB) at 30 days: definite lesion thrombosis, clinically driven TLR, and device-failure-related MI (not clearly attributable to a non-target vessel).

Target Lesion Failure (TLF; ARC-DCB) at all timepoints: composite of cardiovascular death, target-vessel MI, and clinically driven TLR.

Target Vessel Failure (TVF; ARC-DCB) at all timepoints: cardiovascular death, target-vessel MI, and clinically driven target vessel revascularisation.

Target-vessel MI (ARC-DCB) at all timepoints. All-cause mortality and cardiovascular death (per ARC-2 as adopted by ARC-DCB). Any myocardial infarction (Fourth and Fifth Universal Definition of Myocardial Infarction).

Peri-procedural myocardial infarction (ARC-DCB) at discharge and 30 days. Any stroke (ischaemic, haemorrhagic or undetermined; Neuro-ARC) at all timepoints

Any definite lesion thrombosis (ARC-DCB [20]): angiographic confirmation of thrombus originating in, or within 5 mm of, the treated segment, or pathological (autopsy) confirmation, in the presence of an acute ischaemic clinical syndrome. Classified by timing as acute (≤ 24 h), subacute (> 24 h-30 days), late (> 30 days-1 year) and very late (> 1 year).

All TLR, TVR and non-TVR (ARC-DCB) at all timepoints. BARC 3-5 bleeding (BARC [34], as adopted by ARC-DCB) at discharge, 30 days and 1 year

• Angiographic and physiological secondary endpoints (9 months)

Binary restenosis (> 50% diameter stenosis in the target segment at follow-up by QCA; ARC-DCB).

• Procedural endpoints (per ARC-DCB)

Device success (ARC-DCB): successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use), successful withdrawal of the device system, and attainment of a final in-segment residual stenosis of <40% with final data reported by core laboratory QCA.

Procedural success (ARC-DCB): device success and freedom from in-hospital cardiovascular death, TLR, peri-procedural MI, any stroke and BARC 3-5 bleeding.

OCT substudy:

Pre-specified OCT sub-study at participating sites (de novo cohort only) in UK, restricted to subjects whose target lesion has a reference vessel diameter (RVD) ≥ 3.0 mm by visual estimation. In 30 subjects (15 per randomised arm), OCT of the target lesion is acquired at two time points: after lesion preparation (before randomisation and DCB application) and at the 9-month angiographic follow-up and analysed at 1 mm intervals of the treated segment by the OCT core laboratory (CERC).

The primary OCT outcome measure is the percentage change in minimal lumen area from post-lesion preparation to 9 months, compared between BioRISE and SELUTION SLR in 15 subjects per randomised arm (30% lumen-area reduction assumed in both arms, 50% non-inferiority limit, α = 5%, 90% power).

Additional variables include plaque characterisation and dissection after lesion preparation, plaque healing/layering at 9 months and treated-segment lumen volume.

Sub-study analyses are exploratory and do not contribute to the confirmatory analysis of the primary endpoint.

Randomization:

1:1 (BioRISE : SELUTION SLR) via a central, validated electronic randomisation system in the EDC, with concealed allocation, using randomly permuted blocks of variable size, stratified by site. Randomisation is performed after successful lesion preparation (Inclusion Criterion 15) and immediately before device application. The single-arm ISR cohort is not randomised.

Study oversight:

An independent DSMB reviews safety data at pre-specified intervals per the DSMB Charter. An independent Clinical Events Committee (CEC) adjudicates deaths, MI, stroke, lesion thrombosis and revascularisations.

An angiographic core laboratory (CERC) performs QCA/QFR. The study is monitored per a monitoring plan, with data captured in a validated electronic data capture (EDC) system.

Follow-up:

Discharge; 30 days (± 7 days); 9 months (± 30 days, with protocol-mandated coronary angiography - primary endpoint); and 1, 2 and 3 years (± 30 days). Visits are performed in clinic as specified in the follow-up schedule.

Study duration:

Approximately 12 months enrollment; each subject is followed for approximately 3 years. The primary-endpoint analysis is performed after all subjects complete the 9-month angiographic follow-up.

Statistical considerations:

De novo cohort:

Non-inferiority of BioRISE versus SELUTION SLR on in-segment LLL at 9 months. With a margin Δ = 0.19 mm, common SD 0.50 mm, at least 90% power and α = 5% two-sided (2.5% one-sided), 178 evaluable subjects per arm are required; allowing for 11% drop-out, 400 subjects are randomised (200 : 200).

Primary analysis per-protocol with supplementary ITT; non-inferiority is concluded if the upper bound of the two-sided 95% CI for the mean LLL difference (BioRISE - SELUTION SLR) is < 0.19 mm.

If met, superiority is subsequently tested.

ISR cohort:

Single-arm, descriptive; in-segment LLL at 9 months against a performance goal of 0.497 mm (sirolimus arm of SIBLINT and Biolimus arm of BIO-ASCEND ISR; weighted late loss 0.297 mm, weighted SD 0.427 mm). With a margin Δ = 0.2 mm, 80% power and α = 2.5% one-sided, 38 evaluable subjects are required; allowing for 10% drop-out, 43 are enrolled.

Total study enrollment: 443 subjects.

OCT sub-study (de novo cohort): percentage change in MLA from post-lesion preparation to 9 months, 30% expected in both arms, 50% non-inferiority limit, 90% power: 15 subjects per randomised arm (30 in total).

GCP statement and ISO:14155: 2026 This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, ISO 14155:2026 as well as all national legal, MDR and regulatory requirements.

研究の種類

介入

入学 (推定)

443

段階

  • 初期フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Bournemouth、イギリス、BH7 7DW
        • Royal Bournemouth Hospital
        • コンタクト:
      • Bristol、イギリス、BS2 8HW
        • University of Bristol
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • General (all patients):

Age ≥ 18 years

Exclusion Criteria:

  • General (all patients):

    1. Age ≥ 18 years

    2. Documented angina and/or a positive functional ischaemia test, unstable angina, or a stabilized NSTEMI presentation. Patients undergoing index PCI of a non-culprit lesion after AMI may be included in the absence of further documented ischaemia/angina.

    3. Female subjects of childbearing potential have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug.

    4. Eligible for and willing to comply with dual antiplatelet therapy (DAPT).

    5. Life expectancy > 1 year.

    6. Written informed consent obtained from the subject

    7. Willing to comply with all protocol-required follow-up visits, including the 9-month angiographic follow-up.

    8. One or more target vessel (LAD, LCx or RCA) is considered to require intervention and is suitable for treatment with a drug-coated balloon.

    9. Able to tolerate 60 seconds of coronary occlusion for each target lesion.

    10. Reference vessel diameter (RVD) ≥ 1.50 mm and ≤ 4.00 mm by visual estimation.

    11. All target lesions: baseline diameter stenosis > 50% and < 100% with distal flow of at least TIMI 2. For angiographically intermediate lesions where the indication for PCI is uncertain, lesion-specific evidence of ischaemia is demonstrated by an accepted physiological assessment (e.g. FFR, iFR or validated angiography-derived physiology) at baseline.

      De Novo Cohort (Randomised):

    12. A single de novo target lesion

    13. Target lesion length ≤ 36 mm by visual estimation.

    14. In the operator's judgement, the likelihood of requiring provisional/bail-out stenting is < 30% for each randomised target lesion.

    15. Successful lesion predilatation/preparation prior to study DCB delivery: TIMI 3 flow, residual diameter stenosis < 30%, and no flow-limiting or vessel-threatening dissection requiring further treatment or bail-out stenting.

      ISR Cohort (Single-Arm, BioRISE only):

    16. Prior drug-eluting stent (DES) implantation with documented in-stent restenosis (≥ 50% diameter stenosis).

    17. ISR within a single stent layer is permitted. A focal region containing two overlapping stent layers is permitted. ISR involving three or more stent layers is not allowed.

    18. ISR occurring ≥ 1 month after the original stent implantation.

    19. Successful predilatation/preparation: TIMI 3 flow, residual diameter stenosis < 30%

    20. No acute myocardial infarction within 72 hours of the index procedure (per ARC-DCB ISR definition).

Exclusion criteria:

General all patients:

  1. Presentation with STEMI.

  2. Presentation with NSTEMI with ongoing chest pain or haemodynamic instability.

  3. Killip class III (pulmonary oedema) or IV (cardiogenic shock) at presentation.

  4. Chronic NYHA class III or IV heart failure prior to index PCI.

  5. Known LVEF < 30% prior to index PCI.

  6. Known allergy or contraindication to Biolimus, sirolimus or other limus analogues or to the coating excipients, to required antiplatelet/anticoagulant therapy, or to contrast media that cannot be adequately pre-medicated.

  7. Study target lesion located in the left main stem or in any arterial or venous bypass graft.

  8. Renal insufficiency (serum creatinine ≥ 2.0 mg/dL) or dialysis.

  9. Planned major surgery within one month following the index procedure.

  10. Pregnant, breast-feeding, or planning pregnancy during the study period.

  11. Definite or suspected clinically manifest active systemic infection (including clinically manifest COVID-19) at the time of the index procedure.

  12. Currently participating in another investigational device or drug study including PMCFs.

  13. Subject is unable to comply fully with the study protocol.

  14. Subject is under judicial protection, tutorship or curatorship (France only, if selected).

    De Novo Cohort (Randomised) - additional:

  15. Chronic total occlusion (CTO; TIMI flow 0) of a study target lesion.

  16. Any previous PCI (stenting or balloon angioplasty) of the study target vessel, including in-stent restenosis at the target site (such ISR lesions may be eligible for the single-arm ISR cohort).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:BioRISE Biolimus Drug-Coated Balloon

BioRISE is a semi-compliant, rapid-exchange (RX) percutaneous transluminal coronary angioplasty (PTCA) balloon catheter built on the CE-marked RISE™ SC catheter platform with modified hypotube, compatible with a 0.014" guidewire. The device leaves no permanent implant, the only residual is the transferred drug.

Interventions in BioRISE arm aim to improve coronary luminal diameter for the treatment of de novo lesions well as lesions resulting from In-Stent Restenosis

アクティブコンパレータ:SELUTION SLR sirolimus-coated balloon

SELUTION SLR (Cordis / MedAlliance), a sirolimus-coated drug-coated balloon on a 0.014" rapid-exchange PTCA platform, CE-marked and used within its approved intended purpose.

The comparator applies to the de novo randomised cohort only; the single-arm ISR cohort has no comparator.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
In-segment Late Lumen Loss (LLL) at 9 months
時間枠:9 months

The primary endpoint is in-segment late lumen loss at 9 months, defined as the difference between the post-procedural minimal lumen diameter (MLD) and the 9-month follow-up MLD, measured by quantitative coronary angiography (QCA) and assessed by an blinded angiographic core laboratory (ARC-DCB Table 1, item 8).

Analysis segment: in-segment, defined for this study as the balloon-treated segment plus 5 mm proximal and 5 mm distal, consistent with the comparator's pivotal trials (SELUTION DeNovo). ARC-DCB defines in-segment as the treated segment plus 1 mm, the ARC-DCB rationale for in-segment analysis (a proximal and distal buffer zone mitigating geographic miss= applies equally. The core laboratory additionally reports in-segment LLL with the ARC-DCB 1 mm margins.

9 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Secondary outcomes
時間枠:• index procedure • Discharge up to 7 days (patient and hospital practice dependent) • 30 days • 9 months • 1 year • 2 years • 3 years

Device-Oriented Composite Endpoint (DOCE) at all time points Lesion-Oriented Composite Endpoint (LOCE) at 30 days Target Lesion Failure (TLF) at all timepoints Target Vessel Failure (TVF) at all timepoints Target-vessel MI (ARC-DCB) at all timepoints. All-cause mortality and cardiovascular death (per ARC-2 as adopted by ARC-DCB). Any myocardial infarction (Fourth and Fifth Universal Definition of Myocardial Infarction).

Peri-procedural myocardial infarction (ARC-DCB) at discharge and 30 days. Any stroke (ischaemic, haemorrhagic or undetermined; Neuro-ARC) at all timepoints.

Any defined lesion thrombosis. All TLR, TVR and non-TVR (ARC-DCB) at all timepoints. BARC 3-5 bleeding (BARC [34], as adopted by ARC-DCB) at discharge, 30 days and 1 year Binary restenosis (> 50% diameter stenosis in the target segment at follow-up by QCA; ARC-DCB).

Device success Procedural success

• index procedure • Discharge up to 7 days (patient and hospital practice dependent) • 30 days • 9 months • 1 year • 2 years • 3 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年3月1日

一次修了 (推定)

2029年1月31日

研究の完了 (推定)

2031年3月31日

試験登録日

最初に提出

2026年11月2日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する